NKCx Histopathological outcome* within 12 months after cervix cytology in 2021
611 Gävleborg

  Benign LSIL HSIL AIS Cancer Other PAD missing Total
Cytologi Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel Antal Andel
Benign sample 359 3.4% 100 1.0% 26 0.2% . . 1 0.0% 15 0.1% 9989 95.2% 10490 100.0%
ASCUS 146 18.0% 144 17.8% 109 13.5% 2 0.2% 6 0.7% 11 1.4% 392 48.4% 810 100.0%
LSIL 30 16.8% 48 26.8% 58 32.4% . . . . 7 3.9% 36 20.1% 179 100.0%
Atypical glandular cells/AGC 3 20.0% 2 13.3% 3 20.0% 1 6.7% 1 6.7% 1 6.7% 4 26.7% 15 100.0%
Unclear atypia 1 7.7% 1 7.7% 6 46.2% 3 23.1% 2 15.4% . . . . 13 100.0%
ASC-H 6 17.6% 5 14.7% 20 58.8% . . 3 8.8% . . . . 34 100.0%
HSIL 10 7.5% 7 5.2% 106 79.1% . . 5 3.7% . . 6 4.5% 134 100.0%
Adenocarcinoma . . . . . . . . 2 66.7% . . 1 33.3% 3 100.0%
Squamous cell cancer . . . . 1 50.0% . . 1 50.0% . . . . 2 100.0%
Totalt 555 4.8% 307 2.6% 329 2.8% 6 0.1% 21 0.2% 34 0.3% 10428 89.3% 11680 100.0%

NOTE: Histopathological outcome from T83x taken into account.
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad.

* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead.
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'.
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories.
 

Snomed codes in the category
Cancer:
M80703, M81403, M84413